Suchergebnisse - "Maggiolo, Franco"

PubPharm (18)

1

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

enthalten in: AIDS (London, England) | 2024

von Orkin, C. | Antinori, A. | Rockstroh, J. | +11

2

Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures

enthalten in: Journal of global antimicrobial resistance | 2023

von Gagliardini, R. | Lorenzini, P. | Cozzi-Lepri, A. | +9

3

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1) : Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Llibre, J. | Brites, C. | Cheng, C. | +14

CommentIn: Int J Antimicrob Agents. 2023 Aug;62(2):106839. - PMID 37160239

4

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

enthalten in: BMC infectious diseases | 2022

von Maggiolo, F. | Gulminetti, R. | Pagnucco, L. | +5

5

Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort

enthalten in: Journal of the International Association of Providers of AIDS Care | 2022

von Maggiolo, F. | Valenti, D. | Teocchi, R. | +3

6

Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy

enthalten in: International journal of antimicrobial agents | 2021

von Gagliardini, R. | Gianotti, N. | Maggiolo, F. | +11

7

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

enthalten in: The lancet. HIV | 2020

von Orkin, C. | DeJesus, E. | Sax, P. | +20

CommentIn: Lancet HIV. 2020 Jun;7(6):e374-e375. - PMID 32504568

8

Brief Report : Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2020

von Eron, J. | Hung, C. | Baril, J. | +16

9

No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control : Time of viral suppression makes the difference

enthalten in: Antiviral research | 2019

von Giacomelli, A. | Lai, A. | Franzetti, M. | +13

10

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2) : week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

enthalten in: Lancet (London, England) | 2019

von Cahn, P. | Madero, J. | Arribas, J. | +118

CommentIn: Lancet. 2019 Jan 12;393(10167):106-108. - PMID 30420122